BAIYUNSHAN PH (00874) announced its annual results for the period ending December 31, 2025. The group achieved operating revenue of 77.656 billion yuan, representing a year-on-year increase of 3.55%. Net profit attributable to shareholders was 2.983 billion yuan, up 5.21% compared to the previous year. Basic earnings per share stood at 1.835 yuan, with a proposed cash dividend of 0.45 yuan per share.

Throughout 2025, the group consistently focused on its strategic positioning in the biomedicine and health sector. Leveraging its industrial advantages, it fully utilized its resources and assets to comprehensively advance production and operational activities, driving sustained and stable business growth.

The company further promoted the standardization and规范化 construction of traditional Chinese medicine planting bases, continuously strengthening its control over the production and supply of key TCM raw materials. It consolidated its competitive edge in specialty active pharmaceutical ingredients (APIs), enriched its specialty API product portfolio, and intensified efforts to expand into new API products while steadily growing its presence in both domestic and international markets.

BAIYUNSHAN PH continued to deepen collaborations with leading retail chains and e-commerce platforms. It focused on strengthening high-performing products, revitalizing underperforming ones, and cultivating blockbuster new products. Simultaneously, the company maintained a strong emphasis on quality and safety, continuously improving product quality to enhance market competitiveness and support the stable development of its pharmaceutical business.

During the reporting period, several products recorded relatively rapid sales growth compared to the previous year. These included Xiao Ke Wan, Baoji Series, Amoxicillin Series, Angong Niuhuang Wan, Shujin Jianyao Wan, anti-inflammatory and analgesic patches, Methylhesperidin, and Candesartan Cilexetil Tablets.